20.500.12556/DiRROS-8902 Potek bolezni pri bolnicah s HER-2 pozitivnim rakom dojk Clinical course of HER-2 positive breast cancer patients Breast cancer is the most frequent cancer in women. The course and efficiency of breast cancer treatment are influenced by several factors. The expression of HER-2 protein and HER-2 gene is gaining in strength in breast cancer management. The aim of our study was to compare the course of HER-2 positive with HER-2 negative disease. In median time of 2.5 years DFS (disease-free-survival) of patients with HER-2 positive tumours was 76.1%, and 93.4% for patients with HER-2 negative disease. HER-2 status was the strongest prognostic factor for DFS (p true false true Slovenski jezik Angleški jezik by Authors Neznano 2018-08-31 13:32:45 2018-08-31 13:32:45 2022-08-24 17:41:32 0000-00-00 00:00:00 2008 0 0 Soavtorji: Š. Fink, S. Frković Grazio, H. Lešničar, A. Sadikov in T. Čufer; BSDOCID143369; str. 94-98 št. 2 Letn. 12 2008 0000-00-00 Zaloznikova Objavljeno NiDoloceno 0000-00-00 0000-00-00 0000-00-00 616-006 1408-1741 URN:NBN:SI:doc-JJWIMRX6 25343193 65324032 RAZ_Ribnikar_Domen_i2008.pdf RAZ_Ribnikar_Domen_i2008.pdf 1 638CDED6EC4F49FBBB7B7042821809D4 15e165ef894b606e00b78dc61f4b087d4f9f28acc0a3648d2fc386e463b2e397 65852a8d-17b5-11ed-b6b8-001a4af901a5 20.500.12556/dirros/69ac7e30-b53a-4bf5-b31e-9399c58b4807 https://dirros.openscience.si/Dokument.php?lang=slv&id=10683 Onkološki inštitut Ljubljana Onkologija : strokovni časopis za zdravnike 0 0 0